when will eli lilly release retatrutide just released impressive study results for retatrutide, an investigational weight loss drug that targets three hormones—and may deliver more weight loss than current GLP-1s. See link below ⬇️ Eli Lilly stock jumps on

Introduction The gastrointestinal tract harbors an array of hormones and regulatory peptides, involved in control of processes ranging from food intake to glucose homeostasis (1)

In a long-term evaluation of the LEADER trial with 9,340 patients with T2D over a 3.5- to 5-year period, there was no evidence of C-cell malignancies occurred in the liraglutide group [84]

Side effects, if they occur, can also vary in intensity and duration

It also makes you feel less hungry

GIP receptor activation amplifies insulin response and appears to play a role in fat metabolism that researchers are still fully characterizing

For the full scientific overview, see What Is Retatrutide